Evidence map›Paper›PMID 39158810›Full record

ArticlePituitary2024

The comprehensive evaluation of oral and fecal microbiota in patients with acromegaly.

Serdar Sahin, Aycan Gundogdu, Ufuk Nalbantoglu, Zuleyha Karaca, Aysa Hacioglu, Muhammed Emre Urhan, Kursad Unluhizarci, Mehmet Hora, Elif Seren Tanrıverdi, Emre Durcan and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Pituitary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Serdar SahinDepartment of Endocrinology and Metabolic Diseases, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Aycan GundogduDepartment of Microbiology and Clinical Microbiology, School of Medicine, Erciyes University, Kayseri, Turkey.
Ufuk NalbantogluGenome and Stem Cell Center (GenKok), Erciyes University, Kayseri, Turkey.
Zuleyha KaracaDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Erciyes University, Kayseri, Turkey.
Aysa HaciogluDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Erciyes University, Kayseri, Turkey.
Muhammed Emre UrhanDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Erciyes University, Kayseri, Turkey.
Kursad UnluhizarciDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Erciyes University, Kayseri, Turkey.
Mehmet HoraGenome and Stem Cell Center (GenKok), Erciyes University, Kayseri, Turkey.
Elif Seren TanrıverdiMedical Microbiology Laboratory, Malatya Training and Research Hospital, Malatya, Turkey.
Emre DurcanDepartment of Endocrinology and Metabolic Diseases, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Gülsah ElbükenDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Namik Kemal University, Tekirdag, Turkey.
Hatice Sebile DokmetasDepartment of Endocrinology and Metabolic Diseases, University of Health Sciences, Cemil Tascıoğlu City Hospital, Istanbul, Turkey.
Sayid Shafi ZuhurDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Namik Kemal University, Tekirdag, Turkey.
Necmettin TanrioverDepartment of Neurosurgery, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Ugur TüreDepartment of Neurosurgery, School of Medicine, Yeditepe University, Istanbul, Turkey.
Fahrettin KelestimurDepartment of Endocrinology and Metabolic Diseases, School of Medicine, Yeditepe University, Istanbul, Turkey.
Pinar KadiogluDepartment of Endocrinology and Metabolic Diseases, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. kadioglup@yahoo.com.ORCID http://orcid.org/0000-0002-8329-140X

Funding

Scientific Research Projects Coordination Unit of Istanbul University-Cerrahpasa TSA-2020-34925
6 · The paper itself

Abstract

purposeThe alteration of the microbiota in the mouth and gut could potentially play a role in the pathogenesis of various diseases, and conversely, these diseases may have an influence on the composition of the gut microbiota. Acromegaly disease can potentially affect physiological processes in the mouth and gut. The present study was designed to investigate the relationship between acromegaly and the oral and gut microbiota, as data on this topic are scarce.

methodsThis was a multicenter, cross-sectional study. Our study included individuals diagnosed with acromegaly (who were treated and followed up, and also as an another group of patients with newly diagnosed acromegaly) and healthy participants. All three groups were assessed and compared based on age, sex, serum IGF-1, body mass index BMI as well as their stool and oral microbiota We collected demographic information from the patients, collected fecal and oral samples, performed DNA isolation followed by 16 S rRNA sequencing, and then performed bioinformatic analysis. We also analyzed the oral and fecal samples with respect to medical and surgical treatment and disease control status, specific treatments received for acromegaly, presence of comorbidities, hypopituitarism status, presence of intestinal polyps.

resultsOne hundred and three patients with acromegaly, 15 newly diagnosed patients with acromegaly without comorbidities and 34 healthy controls were included in the study. The Firmicutes/Bacteroidetes ratio was significantly lower in patients with acromegaly who received treatment (medical and/or surgical) than in healthy controls. In addition, a significant difference was found in the fecal and oral microbiota of patients with acromegaly with disease control compared to healthy controls. Furthermore, a significant difference was found in the fecal and oral microbiota of patients with acromegaly without disease control. Nevertheless, it was not possible to establish a clear relationship between disease control status, the presence of intestinal polyps, the presence of type 2 diabetes and the composition of the oral and gut microbiota in acromegalic patients who had received different forms of treatment.

conclusionPatients with acromegaly show distinct gut microbiota profiles, and it is evident that factors beyond the GH/IGF-1 axis play a role in shaping the gut microbiota of individuals with acromegaly.

Indexed as

AcromegalyFecesAdultAgedCross-Sectional StudiesFemaleGastrointestinal MicrobiomeHumansInsulin-Like Growth Factor IMaleMicrobiotaMiddle AgedMouthInsulin-Like Growth Factor IAcromegalyGutMicrobiotaOral microbiologyPeriodontitis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.